Headlands Research announced the acquisition of Clinical Trials Research, a privately owned clinical research organization with locations in Sacramento and Lincoln, California. Financial terms of the transaction were not disclosed.
The sites will operate as Headlands Research – Sacramento and Headlands Research – CTR Lincoln.
The acquisition expands Headlands Research’s presence in California and adds two established Sacramento-area clinical trial sites to its network.
Clinical Trials Research brings 25 years of clinical research experience and more than 300 completed Phase I-IV clinical trials.
The sites have built a reputation for rapid study startup, strong patient recruitment, and high-quality data.
Clinical Trials Research has experience across several indications, including high cholesterol, hypertension, heart failure prevention, obesity and overweight, type 2 diabetes, diabetic peripheral neuropathic pain, fatty liver disease, and chronic idiopathic constipation.
Headlands said the acquisition strengthens its cardiometabolic therapeutic area capabilities.
Clinical Trials Research is led by Jeffrey D. Wayne, MD, who has served as a principal investigator since 1992.
Dr. Wayne is a board-certified internist who earned his medical degree from the University of Southern California Keck School of Medicine.
He also serves as clinical faculty at the University of California, Davis School of Medicine.
His research experience includes cardiovascular disease, diabetes, respiratory conditions, and women’s and men’s health.
Headlands Research said the acquisition pairs Clinical Trials Research’s local experience and sponsor relationships with Headlands’ infrastructure and broader site network.
The combination is expected to help bring more patients into research, expand available therapeutic areas for the community, and maintain the quality sponsors rely on.
Headlands Research is a clinical trial site organization focused on advancing innovative medical therapies.
The company operates a network of wholly owned clinical research sites across North America and Europe.
Headlands provides sponsors and CROs with access to experienced investigators, diverse patient populations, and centralized operational support across therapeutic areas including CNS, vaccines, metabolic diseases, obesity, respiratory disease, cardiometabolic disorders, and more.
KEY QUOTES:
“CTR brings something distinct in an acquisition: two established sites, a 25-year history, and a team that sponsors already know and trust. By pairing that depth with Headlands’ infrastructure, we advance our objective of being the partner of choice for pharmaceutical companies and CROs by providing additional capabilities and scale to our cardiometabolic therapeutic area.”
Kyle Burtnett, CEO of Headlands Research
“Clinical research has been my career passion, and our team has built a trusted research practice. Joining Headlands Research gives us the infrastructure and network to bring more patients into research, expand the therapeutic areas that we can offer our community, and maintain the quality our sponsors rely on.”
Jeffrey D. Wayne, MD, Head of Clinical Trials Research
